{
    "clinical_study": {
        "@rank": "151572", 
        "brief_summary": {
            "textblock": "To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis\n      carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim /\n      sulfamethoxazole ( TMX / SMX ); to monitor serious adverse events attributable to 566C80."
        }, 
        "brief_title": "An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have the following:\n\n          -  Clinical diagnosis of acute severe Pneumocystis carinii pneumonia (PCP).\n\n          -  Dose-limiting intolerance to TMP / SMX and parenteral pentamidine.\n\n          -  Willingness and ability to give informed consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Excluded:\n\n          -  Patients with a history of intolerance to 566C80. Patients with the following prior\n             conditions are excluded: History of serious dose-limiting adverse experience during\n             previous 566C80 therapy, thought to be attributable to the drug.\n\n        Required:\n\n          -  Trimethoprim / sulfamethoxazole (TMP/SMX); pentamidine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001990", 
            "org_study_id": "053D", 
            "secondary_id": "33384-10"
        }, 
        "intervention": {
            "intervention_name": "Atovaquone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pentamidine", 
                "Trimethoprim", 
                "Trimethoprim-Sulfamethoxazole Combination", 
                "Atovaquone", 
                "Sulfamethoxazole"
            ]
        }, 
        "keyword": [
            "Trimethoprim-Sulfamethoxazole Combination", 
            "Pneumonia, Pneumocystis carinii", 
            "Pentamidine", 
            "Antifungal Agents", 
            "Acquired Immunodeficiency Syndrome", 
            "atovaquone"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Research Triangle Park", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27709"
                }, 
                "name": "Glaxo Wellcome Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001990"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1993"
    }, 
    "geocoordinates": {
        "Glaxo Wellcome Inc": "35.902 -78.867"
    }
}